Discontinuation of adalimumab without functional and structural damage progression after attaining sustained remission in patients with rheumatoid arthritis: An observational study
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms HONOR
- 08 Dec 2017 Status changed from active, no longer recruiting to completed.
- 03 Oct 2016 Retrospective sub-group analysis data presented at the American College of Rheumatology 2016 Annual Meeting, as per Myriad Genetics media release.
- 01 Jul 2016 Results (correction to citation #3104218) published in the Annals of the Rheumatic Diseases.